



Aalborg Universitet

AALBORG UNIVERSITY  
DENMARK

## Experimental pain in the groin may refer into the lower abdomen

### *Implications to clinical assessments*

Drew, M. K.; Palsson, Thorvaldur Skuli; Hirata, Rogerio Pessoto; Izumi, Masashi; Lovell, G.; Welvaert, M.; Chiarelli, P.; Osmotherly, P. G.; Graven-Nielsen, Thomas

#### *Published in:*

Journal of Science and Medicine in Sport

#### *DOI (link to publication from Publisher):*

[10.1016/j.jsams.2017.04.007](https://doi.org/10.1016/j.jsams.2017.04.007)

#### *Publication date:*

2017

#### *Document Version*

Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

#### *Citation for published version (APA):*

Drew, M. K., Palsson, T. S., Hirata, R. P., Izumi, M., Lovell, G., Welvaert, M., Chiarelli, P., Osmotherly, P. G., & Graven-Nielsen, T. (2017). Experimental pain in the groin may refer into the lower abdomen: Implications to clinical assessments. *Journal of Science and Medicine in Sport*, 20(10), 904-909.  
<https://doi.org/10.1016/j.jsams.2017.04.007>

#### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

#### **Take down policy**

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.

# **Experimental pain in the groin may refer into the lower abdomen: implications to clinical assessments**

M. K. Drew<sup>b,c</sup>, T.S. Palsson<sup>a</sup>, R. P. Hirata<sup>a</sup>, M. Izumi<sup>a,d</sup>,  
G. Lovell<sup>e</sup>, M. Welvaert<sup>f</sup>, P. Chiarelli<sup>b</sup>, P.G. Osmotherly<sup>b</sup>, T. Graven-Nielsen<sup>a,\*</sup>

<sup>a</sup> Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark.

<sup>b</sup> School of Health Sciences, Faculty of Health and Medicine, University of Newcastle, Australia

<sup>c</sup> Department of Physical Therapies, Australian Institute of Sport, Canberra, Australia

<sup>d</sup> Department of Orthopedic Surgery, Kochi University, Japan

<sup>e</sup> Department of Sports Medicine, Australian Institute of Sport, Canberra, Australia

<sup>f</sup> UCRISE, University of Canberra, Canberra, Australia

**Running head:** EMG, mechanical sensitivity, and distribution of experimental groin pain

**Original paper for:** Journal of Science and Medicine in Sport

**Funding sources:** This study received (non-grant) financial support through the University of Newcastle, Australia.

**Conflicts of interest:** None declared

**Ethical approval:** Danish Regional Ethics Committee (N-20130036)

**Word Count:** 3099

**Abstract Word Count:** 249

**Tables:** 1

**Figures:** 2

**Supplements:** 6

**\*Corresponding author:**

Professor Thomas Graven-Nielsen, DMSc, Ph.D.

Center for Neuroplasticity and Pain (CNAP)  
SMI, Department of Health Science and Technology  
Faculty of Medicine  
Aalborg University

Fredrik Bajers Vej 7D-3  
9220 Aalborg E, Denmark  
Phone: +45 9940 9832  
Fax: +45 9815 4008  
<http://www.cnap.hst.aau.dk/>  
E-mail: [tgn@hst.aau.dk](mailto:tgn@hst.aau.dk)

**ABSTRACT**

**Objectives:** To investigate the effects of experimental adductor pain on the pain referral pattern, mechanical sensitivity and muscle activity during common clinical tests.

**Design:** Repeated-measures design

**Methods:** In two separate sessions, 15 healthy males received a hypertonic (painful) and isotonic (control) saline injection to either the adductor longus (AL) tendon to produce experimental groin pain or into the rectus femoris (RF) tendon as a painful control. Pain intensity was recorded on a visual analogue scale (VAS) with pain distribution indicated on body maps. Pressure pain thresholds (PPT) were assessed bilaterally in the groin area. Electromyography (EMG) of relevant muscles was recorded during six provocation tests. PPT and EMG assessment were measured before, during and after experimental pain.

**Results:** Hypertonic saline induced higher VAS scores than isotonic saline ( $p < 0.001$ ), and a local pain distribution in 80% of participants. A proximal pain referral to the lower abdominal region in 33% (AL) and 7% (RF) of participants. Experimental pain (AL and RF) did not significantly alter PPT values or the EMG amplitude in groin or trunk muscles during provocation tests when forces were matched with baseline.

**Conclusions:** This study demonstrates that AL tendon pain was distributed locally in the majority of participants but may refer to the lower abdomen. Experimental adductor pain did not significantly alter the mechanical sensitivity or muscle activity patterns.

**Key Words:** athlete; EMG; pressure pain sensitivity; adductor longus tendon; rectus femoris tendon

## **Introduction**

The prevalence of hip and groin pain in athletes is generally high with a career prevalence of 45% reported in professional Australian football players<sup>1</sup> and a high incidence in sports such as football<sup>2</sup> and ice hockey.<sup>3</sup> Adductor-related groin pain is characterised as pain on resisted adduction and pain on palpation of the adductor longus muscle.<sup>4</sup> In contrast, abdominal symptoms present with pain on resisted trunk flexion and pain on palpation of the rectus abdominis distal enthesis.<sup>5</sup> Yet characteristics of groin pain per se are poorly understood with few reports of pain referral patterns and clinical symptomatology. Pain referral patterns are typically semi- (referring distally) or bi-directional (referring both distally and proximally) with referred pain distributions extending to neighbouring vertebral segments that are supplying the painful muscle or tendon.<sup>6</sup> Clinically, pain in both the adductor and abdominal area is associated with longer recovery times compared to a single site.<sup>7</sup> The role of pain referral patterns has not previously been examined and may present a plausible alternate hypothesis to co-existing pain locations<sup>5, 8-10</sup> in this region. That is, abdominal pain may present clinically as a result of referred pain from the adductor region. If this is true, it challenges using pain location alone as diagnostic criteria in either classifying patients into entities or to specific pathoanatomical tissue diagnoses.

Electromyographic (EMG) muscle activity has been shown to be significantly reduced in m. adductor longus, m. pectineus, and m. gracilis, in patients with a history of groin pain during clinical tests when compared to healthy activity-matched-controls.<sup>11</sup> Such changes occur soon after the initiating painful event.<sup>12</sup> Given the complex relationship between muscle and fascial structures in the groin and abdominal region, this possible reduction in muscle activity could shift the balance of the forces between the adductor and abdominal muscles thus influencing performance during diagnostic testing. If muscle activation patterns change, it may be possible to maintain the same force output despite the existence of a painful condition as shown in other pain states.<sup>13, 14</sup> This may have clinical implications with regards to the interpretation of clinical diagnostic tests due to alterations in muscle activity and also the transition from acute into long-standing groin pain.<sup>15</sup>

Experimental pain caused by injection of hypertonic saline into tendons in healthy participants has been shown to cause increased trunk muscle activity,<sup>16, 17</sup> large pain referral patterns,<sup>16, 18</sup> regional hyperalgesia,<sup>16, 18, 19</sup> and facilitated response to clinical orthopaedic tests for the hips and pelvic girdle.<sup>16, 18, 19</sup> Therefore, a hypertonic saline model may provide insights into the effect of pain in the groin region on the muscle activity, mechanical sensitivity, and referral patterns.

While many studies have focused on the diagnosis of groin pain in athletes, little is understood about the effect of pain itself on the muscle activation during the diagnostic tests, pain referral patterns, and mechanical sensitivity, all of which are recommended diagnostic criteria.<sup>4</sup> This study aimed to examine three hypotheses surrounding experimental pain at the proximal insertion of the adductor longus: 1. The pain experienced can radiate superior to the pubic crest. 2. The pain experienced causes alteration of EMG muscle activity patterns. 3. The pain experienced produces local deep tissue hyperalgesia.

## **Methods**

Fifteen healthy male participants were included for this study (mean  $\pm$  SD; age,  $26.9 \pm 3.4$  years; height,  $183.9 \pm 5.4$  cm; weight,  $81.5 \pm 7.1$  kg). Inclusion criteria were 1) no current or previous hip, groin, or lumbar region injuries; 2) no signs of neurological disorders or rheumatologic diseases which could affect the outcome of the experimental procedure; 3) no reported medication use either on enrolment or on a regular basis; 4) currently participating in regular exercise or sport of total duration of greater than or equal to 2.5 hours a week. Exclusion criteria were current injury, any history of pain or injury in the hip, groin, lower abdominal or lumbar regions, a history of lower limb injury in the previous 2 years, usage of cannabis, opioids or other drugs, current use of pain medication, previous neurologic, musculoskeletal or mental illnesses, or lack of ability to cooperate. Participants were given a detailed verbal and written explanation of the experimental procedure. All participants provided written informed consent. The study was approved by the Danish Regional Ethics Committee (N-20130036) and conducted in accordance with the Helsinki Declaration.

The experiment had a randomized, single-blinded, balanced-crossover, repeated-measures design conducted in two sessions within one week. Randomisation was achieved through the selection of one of 16 identical envelopes by an experimenter (blinded to the injector and experimenters) containing one of all 16 possible order combinations of injection site, side, and injection site. Blinding was achieved through unlabelled, identical pre-prepared syringes prior to the experimenters entering the room. The participants were not advised of the order of injections at any stage throughout the procedure.<sup>20</sup> Experimental groin pain and a painful control condition outside the groin area were evaluated. Clinical provocation tests with recordings of the muscle activity and assessment of the pressure pain sensitivity were administered at baseline, during and after (post-pain) experimental pain with participant lying supine on a plinth. Prior to baseline testing, all participants were familiarised with the experimental procedure and confirmed to be pain-free prior to commencing the study. The post-pain state was defined as five minutes after the cessation of experimental pain.

The participants participated in two sessions and received one hypertonic and one isotonic saline injection each session, one in each side of the same site (AL or RF) during each session. The alternate site was injected in the following session. The order of the saline type (hypertonic or isotonic) and site (AL or RF) and side (left or right) was randomised in a balanced way. Groin pain was induced by injecting sterile hypertonic saline (1 ml, 5.8%) into the adductor longus (AL) tendon with isotonic saline (1 ml, 0.9%) injected as a non-painful control into the same anatomical site on the contralateral side within the same session. As a positive (painful) control injection outside the groin area, the proximal tendon of the long head of the rectus femoris (RF) muscle was injected in a separate session. The same volume of hypertonic or isotonic saline was injected into the control site as designated by the randomisation. Participants and injector were blinded to saline type administered. All injections were given by an orthopaedic surgeon (MI). After a standard disinfection protocol, the injections were given over the duration of approximately 10 seconds using a 2-ml plastic syringe with a disposable needle (27G). Pre-defined anatomical landmarks for injection sites for AL and RF tendons were utilised. The location, depth and alignment of all injection sites were confirmed by real time

ultrasound (US) imaging (*Acuson 128XP10, NativeTM*). The AL tendon was identified using a method previously described.<sup>18</sup> Both the AL and RF injections positions followed a previously published protocol (Supplement 1).<sup>20</sup>

The pain intensity produced by hypertonic saline injections was assessed on a 10 cm electronic visual analogue scale (VAS) which could be adjusted by using an external handheld slider. The VAS was anchored with ‘no pain’ and ‘maximum pain’, 0 cm and 10 cm, respectively. A continuous recording (sample frequency of 20 Hz) of the VAS signal was made after each injection until all pain had subsided. For analysis, the area under VAS-time curve (VAS area) and VAS-peak were extracted.

The quality of pain was assessed once the pain had subsided. Participants were allowed to answer using either the Danish<sup>21</sup> or English<sup>22</sup> version of the McGill Pain Questionnaire based upon their language preference. The Danish results were converted to the English equivalent for analysis. Participants were asked to mark their pain distribution by filling in a standard body chart. Body areas were divided into groin regions by using the “Groin Triangle”.<sup>23</sup> The groin triangle is defined as the triangle created by the three landmarks: the anterior superior iliac spine (ASIS), pubic tubercle and the median point between the ASIS and the superior pole of the patella in the anterior coronal plane (‘3G point’).<sup>24</sup> Local pain was defined as pain experienced only at the injection site and related “Groin Triangle” segment while referred pain was defined as any pain felt outside the segment containing the injection site. The body regions were analysed by registering the frequency of pain experienced in the region for all four injections.

Pressure pain thresholds (PPTs) were assessed at regional and distant sites using a handheld pressure algometer (*Somedic, Sweden*) with a 1 cm<sup>2</sup> probe and using a 30 kPa/s ramp. The four bilateral assessment sites were the AL tendon injection site, the RF tendon injection site, the anterior surface of the superior pubic rami (PB), and the tibialis anterior (TA) muscle, measured as the proximal site 1/3 the distance from the lateral joint line of the knee to the inferior aspect of the lateral malleolus. Each

measurement was recorded three times at baseline with two measurements recorded during pain and post-pain to ensure all testing could be completed within the short-lasting window of saline-induced pain. The average of the measurements was used for statistical analysis. PPT measurement was ceased at 1200 kPa to avoid sensitisation after repeated assessments.

A battery of six pain provocation tests (Supplement 2) was employed with all tests performed by a single clinically-trained experimenter (MD). All participants were confirmed to be pain-free on all tests prior commencing the study. The tests administered were as previously published:<sup>20</sup> 1) Bilateral adduction (squeeze) test with hips at 0° resisted at the ankles<sup>25</sup> 2) A bilateral squeeze test<sup>11</sup> with hips flexed at 45° 3) A bilateral squeeze test<sup>11</sup> with hips flexed to 90° 4) Resisted abdominal crunch<sup>25</sup> 5) Resisted oblique crunch, one side at a time.<sup>25</sup> The force of contraction was measured using a hand-held dynamometer (*MicroFET2, Hoggan Health Industries, USA*) at baseline, during-pain and post-pain. The reliability of the 0° adduction test is high (ICC = 0.97, minimal detectable change (%) = 6.6).<sup>26</sup> Verbal encouragement by the assessor was given to ensure force output remained constant for each repetition (within 10% of baseline measures).

The skin at each assessment site was shaved, abraded and cleaned with alcohol in accordance with the SENIAM guidelines.<sup>27</sup> Disposable electrodes (*Ambu®, Neuroline 720, Denmark*) were mounted bilaterally with an inter-electrode distance of 20 mm in a bipolar configuration at the m. tensor fasciae latae (TFL), the m. adductor longus (AL), m. rectus abdominis (RA), and m. external obliques (EO).<sup>11</sup>

<sup>28</sup> A ground electrode was placed on the right wrist. The EMG signal from the AL muscle was used as reference to determine the time window for the amplitude analysis (from onset to offset)<sup>29</sup> where the root-mean-square (RMS) value was extracted for all muscles during all six tests for the middle epoch defined as middle third of the period between onset and offset (see Supplement 1 for extended methodology). The RMS value represents the muscle activity of the muscle. The onsets and offsets were automatically detected based on the AL muscle EMG data as previously described in detail by Santello et al.<sup>29</sup> All onset/offset detections were confirmed by visual inspection at each time point. No



manual correction of the data was required. Onsets and offsets were not analysed as the research question investigated related to maximal muscle activity pre-, during and post-experimental pain conditions rather than changes in the order of activation as a result of pain. Filtered EMG data was utilised for analysis however filter and normalised data to baseline measures is reported in the supplements for the ease of interpretation clinically.

All data was assessed for normality using the Kolmogorov–Smirnov test. Means and standard deviations (SD) are presented for parametric data. All statistical analyses were performed using Stata 13 IC unless indicated (*StataCorp, USA*). An *a priori* estimate of group size indicated 15 participants were required (estimated 20% difference in effect parameters;  $\alpha=5\%$ ;  $\beta=20\%$ ; coefficient of variance=25%). The VAS area was analysed with an analysis of variance (ANOVA) with muscle (*AL and RF*) and injection (*hypertonic and isotonic*) as independent factors. To assess the relationship of PPTs and the injection site, side and injection type, a linear mixed-effect model (restricted maximum likelihood [REML] regression) was fitted with PPT site (*AL, pubic bone, RF, and tibialis anterior*), injection type (*hypertonic and isotonic*), side (ipsi- or contralateral) and injection site (*RF and AL*) and time (*baseline, during or post*) and their interactions as fixed-effects. For analysis, filtered EMG data was utilised to assess the relationship between mean RMS-EMG of each clinical test and the effects of injection type (*isotonic and hypertonic*), time point (*baseline, during, post-pain*), each muscle (*AL, TFL, EO, RA*), injection site (*AL and RF*) and side (*ipsilateral and contralateral*) and their interactions with a random effect for participant in a General Linear Mixed Model using the R package lme4 (R Core Team, 2016).<sup>30</sup> This approach can handle missing data which created an unbalanced design.<sup>31</sup> Means were analysed *post-hoc* to explain significant effects. Bonferroni correction was applied where multiple *post-hoc* analyses were undertaken. Significance was set at  $p<0.05$  for all statistical tests.

## Results

The VAS area after hypertonic saline injected into the AL ( $13112 \pm 11147$  mm·s) and RF ( $12110 \pm 8829$  mm·s) tendons were higher compared with isotonic saline (AL:  $206 \pm 405$  mm·s; RF:  $815 \pm 2037$  mm·s; ANOVA:  $F(2,53)=20.05$ ,  $p<0.001$ ). The VAS-peaks reported for each test condition were AL isotonic ( $2 \pm 4$ mm), AL hypertonic ( $22 \pm 12$  mm), RF isotonic ( $4 \pm 7$  mm), and RF hypertonic ( $22 \pm 12$  mm). The three most common words to describe the sensation after the AL tendon hypertonic injections were “annoying” (33% of participants), “tugging” (27%) and “pressing” (27%) whereas the three most common descriptions after the RF tendon hypertonic injections “tight” (47%), “pressing” (33%), “annoying” (27%) for RF tendon.

Hypertonic saline-induced pain in the AL tendon primarily demonstrated a local pattern of pain where it was mainly perceived within and medial to the “Groin Triangle” but also in the lower abdominal region (Figure 1, Table 1). Injections of hypertonic saline into the RF tendon primarily caused pain experienced within the triangle and the anterior and lateral thigh indicating a larger pain referral pattern. During isotonic saline injections into the RF tendon, 11 participants drew the pain on the anterior thigh. Pain in the contralateral side to the injection was also reported in one participant in three areas (Figure 1) after the hypertonic injection into the RF tendon. No participants reported pain on the contralateral side with an absence of pain in the ipsilateral injection side. Therefore, these reports should be considered as bilateral pain distributions.

PPT values did not significantly change across time periods under any conditions. Significant fixed effects were observed for the RF (REML: Coeff=362.5, 95%CI 265.8-564.2,  $p<0.001$ ) and TA sites (REML: Coeff=469.8, 95%CI 374.8-561.8,  $p<0.001$ ) indicating that the TA and RF sites were generally higher than the adductor and pubic sites. However, no significant fixed effects or interactions were observed with the inclusion of time ( $p=0.27-0.99$ ). As time was not a significant fixed effect, this can be interpreted as the PPT values were not significantly influenced by experimental pain conditions. The distributions of PPT values across the experimental conditions and time points are presented in Figure 2.

The magnitude of the muscle activity did not change significantly across time periods under any conditions when compared to baseline conditions. Normalised RMS-EMG for the “during” and “post” conditions are presented in Supplementary Tables 1-4. A five-way interaction between clinical test, injection type, muscle, injection site and side was observed ( $F(15,7771)=8.68$ ,  $p<0.001$ ) however time was not a significant fixed effect in the model or any interactions. As time was not a significant fixed effect it can be interpreted as the muscle activation patterns of the four muscles varied across the clinical tests, injection type and site, and side when compared to each other yet were not significantly uninfluenced by the experimental pain. Therefore, no *post-hoc* analyses were performed.

## Discussion

This is the first study to report the muscle activation pattern involved in commonly used clinical tests for groin pain and mechanical sensitivity of the lower limb in an experimental pain model. This study aimed to examine three hypotheses surrounding experimental pain at the proximal insertion of the adductor longus. The results of this study support the hypothesis that experimental pain in the proximal adductor longus can proximally refer to the lower abdomen and may explain why pain can be experienced in both locations clinically. This study fails to provide evidence that experimental pain in the AL alters the muscle activity and produces local or widespread deep tissue hyperalgesia. These findings have implications for clinical assessment particularly related to diagnostic or classification criteria which rely on pain referral patterns as they can be influenced by region structures.

The AL tendon produced a local pain distribution contained mainly medial to and within the “Groin Triangle”. Moreover, in 33% of participants the tendon of adductor longus was capable of provoking proximal referral into the lower abdominal region. This has clinical relevance as it is commonly reported in the literature that multiple pathologies or clinical entities exist in athletes with groin pain.<sup>5</sup> Experimentally-induced AL tendon pain is capable of producing false positive test results with abdominal manoeuvres.<sup>20</sup> Therefore, comprehensive clinical assessment is required to rule out

involvement of AL tendon when pain in the lower abdomen is present particularly when coexisting with pain in the upper inner thigh. The results of experimental pain models<sup>20</sup> indicate that 45° and 90° adduction tests have the best negative likelihood ratio, suggesting their utility to rule out adductor longus as a potential source of nociception. The positive control condition (experimental RF tendon pain) produced a greater distribution of pain covering the regions within, lateral to and superior to the groin triangle although no pain was reported medial to the triangle. Bilateral leg pain distribution was produced in one participant under the RF tendon hypertonic and isotonic saline conditions. This represents an unusual pain referral pattern that is not typically observed clinically and may be related to individual characteristics of the participant.

In the present study, pain induced in adductor and thigh regions was unable to alter the mechanical sensitivity. Primary mechanical hyperalgesia of the adductor longus tendon has been reported in Australian football players currently experiencing groin pain.<sup>1</sup> This indicates the hypertonic saline tendon pain model may not replicate the clinical pain presentations of groin region. Proximal (secondary) hyperalgesia has been hypothesised to be explained by amplification of central pain mechanisms.<sup>32</sup> No change was observed at the pubic bone or distally on either sides which concurs with clinical pain studies of the groin region.<sup>1</sup> The diagnostic criteria for adductor-related groin pain are pain on resisted adduction tests with tenderness (mechanical sensitivity) on palpation.<sup>4</sup> In acute groin injuries, palpation (mechanical sensitivity) has the greatest diagnostic capacity to predict MRI findings.<sup>33</sup> In the present study, no changes were observed at the site of the injection or on the pubic bone PTTs under the AL or RF ipsilateral hypertonic saline-induced pain indicating secondary mechanical hyperalgesia is less of a concern for this site. Therefore, hyperalgesia of the pubic bone may represent local mechanical hyperalgesia rather than regional/widespread pain and as such may be implicated as a nociceptive driver. Clinically, mechanical sensitivity (tenderness on palpation) at the pubic enthesis may represent local nociception rather than a consequence of adductor tendon pain (as in the case of secondary hyperalgesia). Confirmation in the clinical setting is warranted however.

The magnitude of muscle activity in the region during the painful condition was not statistically significantly different from the baseline condition. This is hypothesised to be due to the study design in which force was maintained equal to baseline measures. This indicates that irrespective of pain in the region, the motor cortex may allow for the task to be completed with equal force production. The 0° adduction test has been suggested to be diagnostically superior to identify experimentally-induced, adductor-related pain.<sup>20</sup> However, the results of this paper indicate that changes in muscle activation less likely to be associated with the diagnostic capabilities reported. Again, this hypothesis should be tested in clinical populations.

This study allowed the evaluation of the outcome measures under controlled conditions. This removes the complications of multiple pathologies detected on clinical assessment<sup>5</sup> and imaging<sup>8</sup> in athletes with groin pain. Nonetheless, pain generated from experimental models differs from clinical pain<sup>18</sup> and replication of the results in clinical populations is warranted as previously indicated. In the analysis of PPT and EMG data, a unified linear mixed model was chosen given its ability to account for the characteristics of the data and to reduce the Type I error associated with multiple sub-grouping analyses. The lack of positive findings observed may be potentially explained by lower power however this is offset by the degrees of freedom created by every participant undertaking each component of the study. Significant variability in the data was observed in the PPT and the level of pain (VAS) measures across participants. This variability reduced the ability to obtain significant effects; an increase in sample size is unlikely to alter the results and are likely to represent the individual nature of the response to pain. *Post-hoc* power analyses are therefore not indicated.<sup>34</sup>

## Conclusion

This study has shown that pain arising from the adductor longus tendon is locally distributed in the majority (80%) but capable of producing pain superior to the pubic crest in 33% of participants. PPTs were not altered by experimental pain induced by hypertonic saline. An alteration of the magnitude of EMG activity of the adductor longus, tensor fascia latae, rectus abdominis and external obliques was

296 not detected under experimental pain conditions when force was matched to baseline measures.  
297 Therefore, diagnostic criteria based on pain distribution alone may be influenced by pain itself in the  
298 region and may not represent tissue pathology or multiple clinical entities of groin pain.

299

300

301

## **Practical Implications**

- The adductor longus tendon has a local pattern of pain distribution however can refer proximally to the lower abdominal region.
- Diagnostic criteria based on pain distribution are potentially influenced by pain itself in the region and may not represent tissue pathology.

## **Acknowledgements**

The authors would like to thank Dr XXX XXXX and Prof. XXX XXXX for their assistance with the statistical analyses. This study received (non-grant) funding from the University of XXX and the XXX.

## **Conflict of interest**

There are no conflicts of interest of the authors.

315 **References**

- 316 1. Drew MK, Palsson TS, Lovell G, Chiarelli PE, Osmotherly PG. Do Australian Football  
317 players have sensitive groins? Players with current groin pain exhibit mechanical hyperalgesia  
318 of the adductor tendon. *J. Sci. Med. Sport.* 2016; 19(10):784-788.
- 319 2. Werner J, Hägglund M, Walden M, Ekstrand J. UEFA injury study: a prospective study of hip  
320 and groin injuries in professional football over seven consecutive seasons. *Br. J. Sports Med.*  
321 2009; 43(1):1036-1040.
- 322 3. Dalton SL, Zupon AB, Gardner EC, Djoko A, Dompier TP, Kerr ZY. The Epidemiology of  
323 Hip/Groin Injuries in National Collegiate Athletic Association Men's and Women's Ice  
324 Hockey. *Orthopaedic Journal of Sports Medicine.* 2016; 4(3):2325967116632692.
- 325 4. Weir A, Brukner P, Delahunt E, et al. Doha agreement meeting on terminology and  
326 definitions in groin pain in athletes. *Br. J. Sports Med.* 2015; 49(12):768-774.
- 327 5. Holmich P. Long-standing groin pain in sportspeople falls into three primary patterns, a  
328 "clinical entity" approach: a prospective study of 207 patients. *Br. J. Sports Med.* 2007;  
329 41(4):247-252.
- 330 6. Graven-Nielsen T. Fundamentals of muscle pain, referred pain, and deep tissue hyperalgesia.  
331 *Scand. J. Rheumatol. Suppl.* 2006; 122:1-43.
- 332 7. Hölmich P, Thorborg K, Dehlendorff C, Krogsgaard K, Glud C. Incidence and clinical  
333 presentation of groin injuries in sub-elite male soccer. *Br. J. Sports Med.* 2014; 48(16):1245-  
334 1250.
- 335 8. Branci S, Thorborg K, Bech BH, Boesen M, Nielsen MB, Hölmich P. MRI findings in soccer  
336 players with long-standing adductor-related groin pain and asymptomatic controls. *Br. J.*  
337 *Sports Med.* 2014; 49(10):681-691.
- 338 9. Branci S, Thorborg K, Nielsen MB, Holmich P. Radiological findings in symphyseal and  
339 adductor-related groin pain in athletes: a critical review of the literature. *Br. J. Sports Med.*  
340 2013; 47(10):611-619.
- 341 10. Weir A, de Vos RJ, Moen M, Holmich P, Tol JL. Prevalence of radiological signs of  
342 femoroacetabular impingement in patients presenting with long-standing adductor-related  
343 groin pain. *Br. J. Sports Med.* 2011; 45(1):6-9.
- 344 11. Lovell GA, Blanch PD, Barnes CJ. EMG of the hip adductor muscles in six clinical  
345 examination tests. *Phys Ther Sport.* 2012; 13(2):134-140.
- 346 12. Jansen JA, Poot B, Mens JMA, Backx FJG, Stam HJ. The Effect of Experimental Groin Pain  
347 on Abdominal Muscle Thickness. *Clin. J. Pain.* 2010; 26(4):300-305.
- 348 13. Cagnie B, Dirks R, Schouten M, Parlevliet T, Cambier D, Danneels L. Functional  
349 reorganization of cervical flexor activity because of induced muscle pain evaluated by muscle  
350 functional magnetic resonance imaging. *Man Ther.* 2011; 16(5):470-475.
- 351 14. Falla D, Farina D, Graven-Nielsen T. Experimental muscle pain results in reorganization of  
352 coordination among trapezius muscle subdivisions during repetitive shoulder flexion. *Exp.*  
353 *Brain Res.* 2007; 178(3):385-393.
- 354 15. Graven-Nielsen T, Arendt-Nielsen L. Impact of clinical and experimental pain on muscle  
355 strength and activity. *Curr Rheumatol Rep.* 2008; 10(6):475-481.
- 356 16. Palsson TS, Hirata RP, Graven-Nielsen T. Experimental Pelvic Pain Impairs the Performance  
357 During the Active Straight Leg Raise Test and Causes Excessive Muscle Stabilization. *Clin.*  
358 *J. Pain.* 2015; 31(7):642-651.
- 359 17. Arendt-Nielsen L, Graven-Nielsen T, Sværre H, Svensson P. The influence of low back pain  
360 on muscle activity and coordination during gait: a clinical and experimental study. *Pain.*  
361 1996; 64(2):231-240.
- 362 18. Izumi M, Petersen KK, Arendt-Nielsen L, Graven-Nielsen T. Pain referral and regional deep  
363 tissue hyperalgesia In experimental human hip pain models. *Pain.* 2014; 155(4):792-800.
- 364 19. Palsson TS, Graven-Nielsen T. Experimental pelvic pain facilitates pain provocation tests and  
365 causes regional hyperalgesia. *Pain.* 2012; 153(11):2233-2240.



20. Drew MK, Palsson TS, Izumi M, et al. Resisted adduction in hip neutral is a superior provocation test to assess adductor longus pain: An experimental pain study. *Scand. J. Med. Sci. Sports.* 2016; 26(8):967-974.
21. Drewes AM, Helweg-Larsen S, Petersen P, et al. McGill Pain Questionnaire translated into Danish: experimental and clinical findings. *Clin. J. Pain.* 1993; 9(2):80-87.
22. Melzock R, Torgerson W. On the language of pain. *Anesthesiology.* 1971; 34(1):50-59.
23. Falvey EC, Franklyn-Miller A, McCrory PR. The groin triangle: a patho-anatomical approach to the diagnosis of chronic groin pain in athletes. *Br. J. Sports Med.* 2008; 43(3):213-220.
24. Franklin-Miller A, Falvey E, McCrory P. Landmarks for the 3G approach: groin, gluteal, and greater trochanter triangles, a pathoanatomical method in sports medicine. *Eur J Anat.* 2008; 12(1):81-87.
25. Holmich P, Holmich LR, Bjerg AM. Clinical examination of athletes with groin pain: an intraobserver and interobserver reliability study. *Br. J. Sports Med.* 2004; 38(4):446-451.
26. Light N, Thorborg K. The precision and torque production of common hip adductor squeeze tests used in elite football. *J. Sci. Med. Sport.* 2015.
27. Hermens HJ, Freriks B, Merletti R, et al. SENIAM 8:European Recommendations for Surface ElectroMyoGraphy: Roessingh Research and Development 1999.
28. Hu H, Meijer OG, Van Dieen JH, et al. Muscle activity during the active straight leg raise (ASLR), and the effects of a pelvic belt on the ASLR and on treadmill walking. *J. Biomech.* 2010; 43(3):532-539.
29. Santello M, McDonagh M. The control of timing and amplitude of EMG activity in landing movements in humans. *Exp. Physiol.* 1998; 83(6):857-874.
30. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. 2015. 2015; 67(1):48.
31. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. *Biometrics.* 1986:805-820.
32. Schaible HG. Basic mechanisms of deep somatic tissue, in *Textbook of Pain*. McMahon SB, Koltzenburg M, eds. Philadelphia, Elsevier/Churchill Livingstone, 2006.
33. Serner A, Weir A, Tol JL, et al. Can standardised clinical examination of athletes with acute groin injuries predict the presence and location of MRI findings? *Br. J. Sports Med.* 2016.
34. Hoenig JM, Heisey DM. The abuse of power. *The American Statistician.* 2012.

## TABLES

**Table 1** Frequency of pain relative to the “Groin Triangle” following injections of hypertonic and isotonic saline into the adductor longus and rectus femoris tendons.

|                           | Adductor Longus Tendon |               |                   |               | Rectus Femoris Tendon |               |                   |               |
|---------------------------|------------------------|---------------|-------------------|---------------|-----------------------|---------------|-------------------|---------------|
|                           | Isotonic saline        |               | Hypertonic saline |               | Isotonic saline       |               | Hypertonic saline |               |
|                           | Ipsilateral            | Contralateral | Ipsilateral       | Contralateral | Ipsilateral           | Contralateral | Ipsilateral       | Contralateral |
| <b>“Groin Triangle”</b>   |                        |               |                   |               |                       |               |                   |               |
| Within the triangle       | 3 (20)                 | 0             | 12 (80 %)         | 0             | 4 (27%)               | 1 (7%)        | 15 (100%)         | 2 (13%)       |
| Lateral to the triangle   | 0                      | 0             | 1 (7 %)           | 0             | 0                     | 0             | 2 (13%)           | 0             |
| Medial to the triangle    | 7 (47)                 | 0             | 12 (80%)          | 0             | 0                     | 0             | 0                 | 0             |
| Superior to the triangle  | 0                      | 0             | 5 (33 %)          | 0             | 0                     | 0             | 1 (7%)            | 0             |
| <b><i>Other areas</i></b> |                        |               |                   |               |                       |               |                   |               |
| Greater Trochanter        | 0                      | 0             | 0                 | 0             | 0                     | 0             | 0                 | 2 (13%)       |
| Anterior Thigh            | 0                      | 0             | 1 (7 %)           | 0             | 2 (13%)               | 0             | 5 (33%)           | 2 (13%)       |
| Lateral Thigh             | 0                      | 0             | 0                 | 0             | 0                     | 0             | 4 (27%)           | 1 (7%)        |
| Knee                      | 0                      | 0             | 0                 | 0             | 0                     | 0             | 0                 | 1 (7%)        |
| Lower Leg                 | 0                      | 0             | 0                 | 0             | 0                     | 0             | 1 (7%)            | 2 (13%)       |
| Foot                      | 0                      | 0             | 0                 | 0             | 0                     | 0             | 0                 | 0             |

Contralateral/Ipsilateral relative to the side of injection; frequencies reported as number of responses (percentage)

## **FIGURE LEGENDS**

**Figure 1** Pain distributions of the adductor longus are indicated on the body chart's right side.

**Figure 2** Distribution of the pressure pain thresholds at baseline, during pain and post-pain across injection types and sites represented as a box-plot.

## ABSTRACT

**Objectives:** To investigate the effects of experimental adductor pain on the pain referral pattern, mechanical sensitivity and muscle activity during common clinical tests.

**Design:** Repeated-measures design

**Methods:** In two separate sessions, 15 healthy males received a hypertonic (painful) and isotonic (control) saline injection to either the adductor longus (AL) tendon to produce experimental groin pain or into the rectus femoris (RF) tendon as a painful control. Pain intensity was recorded on a visual analogue scale (VAS) with pain distribution indicated on body maps. Pressure pain thresholds (PPT) were assessed bilaterally in the groin area. Electromyography (EMG) of relevant muscles was recorded during six provocation tests. PPT and EMG assessment were measured before, during and after experimental pain.

**Results:** Hypertonic saline induced higher VAS scores than isotonic saline ( $p < 0.001$ ), and a local pain distribution in 80% of participants. A proximal pain referral to the lower abdominal region in 33% (AL) and 7% (RF) of participants. Experimental pain (AL and RF) did not significantly alter PPT values or the EMG amplitude in groin or trunk muscles during provocation tests when forces were matched with baseline.

**Conclusions:** This study demonstrates that AL tendon pain was distributed locally in the majority of participants but may refer to the lower abdomen. Experimental adductor pain did not significantly alter the mechanical sensitivity or muscle activity patterns.

**Key Words:** athlete; EMG; pressure pain sensitivity; adductor longus tendon; rectus femoris tendon

## **Introduction**

The prevalence of hip and groin pain in athletes is generally high with a career prevalence of 45% reported in professional Australian football players<sup>1</sup> and a high incidence in sports such as football<sup>2</sup> and ice hockey.<sup>3</sup> Adductor-related groin pain is characterised as pain on resisted adduction and pain on palpation of the adductor longus muscle.<sup>4</sup> In contrast, abdominal symptoms present with pain on resisted trunk flexion and pain on palpation of the rectus abdominis distal enthesis.<sup>5</sup> Yet characteristics of groin pain per se are poorly understood with few reports of pain referral patterns and clinical symptomatology. Pain referral patterns are typically semi- (referring distally) or bi-directional (referring both distally and proximally) with referred pain distributions extending to neighbouring vertebral segments that are supplying the painful muscle or tendon.<sup>6</sup> Clinically, pain in both the adductor and abdominal area is associated with longer recovery times compared to a single site.<sup>7</sup> The role of pain referral patterns has not previously been examined and may present a plausible alternate hypothesis to co-existing pain locations<sup>5, 8-10</sup> in this region. That is, abdominal pain may present clinically as a result of referred pain from the adductor region. If this is true, it challenges using pain location alone as diagnostic criteria in either classifying patients into entities or to specific pathoanatomical tissue diagnoses.

Electromyographic (EMG) muscle activity has been shown to be significantly reduced in m. adductor longus, m. pectineus, and m. gracilis, in patients with a history of groin pain during clinical tests when compared to healthy activity-matched-controls.<sup>11</sup> Such changes occur soon after the initiating painful event.<sup>12</sup> Given the complex relationship between muscle and fascial structures in the groin and abdominal region, this possible reduction in muscle activity could shift the balance of the forces between the adductor and abdominal muscles thus influencing performance during diagnostic testing. If muscle activation patterns change, it may be possible to maintain the same force output despite the existence of a painful condition as shown in other pain states.<sup>13, 14</sup> This may have clinical implications with regards to the interpretation of clinical diagnostic tests due to alterations in muscle activity and also the transition from acute into long-standing groin pain.<sup>15</sup>

Experimental pain caused by injection of hypertonic saline into tendons in healthy participants has been shown to cause increased trunk muscle activity,<sup>16, 17</sup> large pain referral patterns,<sup>16, 18</sup> regional hyperalgesia,<sup>16, 18, 19</sup> and facilitated response to clinical orthopaedic tests for the hips and pelvic girdle.<sup>16, 18, 19</sup> Therefore, a hypertonic saline model may provide insights into the effect of pain in the groin region on the muscle activity, mechanical sensitivity, and referral patterns.

While many studies have focused on the diagnosis of groin pain in athletes, little is understood about the effect of pain itself on the muscle activation during the diagnostic tests, pain referral patterns, and mechanical sensitivity, all of which are recommended diagnostic criteria.<sup>4</sup> This study aimed to examine three hypotheses surrounding experimental pain at the proximal insertion of the adductor longus: 1. The pain experienced can radiate superior to the pubic crest. 2. The pain experienced causes alteration of EMG muscle activity patterns. 3. The pain experienced produces local deep tissue hyperalgesia.

## **Methods**

Fifteen healthy male participants were included for this study (mean  $\pm$  SD; age,  $26.9 \pm 3.4$  years; height,  $183.9 \pm 5.4$  cm; weight,  $81.5 \pm 7.1$  kg). Inclusion criteria were 1) no current or previous hip, groin, or lumbar region injuries; 2) no signs of neurological disorders or rheumatologic diseases which could affect the outcome of the experimental procedure; 3) no reported medication use either on enrolment or on a regular basis; 4) currently participating in regular exercise or sport of total duration of greater than or equal to 2.5 hours a week. Exclusion criteria were current injury, any history of pain or injury in the hip, groin, lower abdominal or lumbar regions, a history of lower limb injury in the previous 2 years, usage of cannabis, opioids or other drugs, current use of pain medication, previous neurologic, musculoskeletal or mental illnesses, or lack of ability to cooperate. Participants were given a detailed verbal and written explanation of the experimental procedure. All participants provided written informed consent. The study was approved by the Danish Regional Ethics Committee (N-20130036) and conducted in accordance with the Helsinki Declaration.

The experiment had a randomized, single-blinded, balanced-crossover, repeated-measures design conducted in two sessions within one week. Randomisation was achieved through the selection of one of 16 identical envelopes by an experimenter (blinded to the injector and experimenters) containing one of all 16 possible order combinations of injection site, side, and injection site. Blinding was achieved through unlabelled, identical pre-prepared syringes prior to the experimenters entering the room. The participants were not advised of the order of injections at any stage throughout the procedure.<sup>20</sup> Experimental groin pain and a painful control condition outside the groin area were evaluated. Clinical provocation tests with recordings of the muscle activity and assessment of the pressure pain sensitivity were administered at baseline, during and after (post-pain) experimental pain with participant lying supine on a plinth. Prior to baseline testing, all participants were familiarised with the experimental procedure and confirmed to be pain-free prior to commencing the study. The post-pain state was defined as five minutes after the cessation of experimental pain.

The participants participated in two sessions and received one hypertonic and one isotonic saline injection each session, one in each side of the same site (AL or RF) during each session. The alternate site was injected in the following session. The order of the saline type (hypertonic or isotonic) and site (AL or RF) and side (left or right) was randomised in a balanced way. Groin pain was induced by injecting sterile hypertonic saline (1 ml, 5.8%) into the adductor longus (AL) tendon with isotonic saline (1 ml, 0.9%) injected as a non-painful control into the same anatomical site on the contralateral side within the same session. As a positive (painful) control injection outside the groin area, the proximal tendon of the long head of the rectus femoris (RF) muscle was injected in a separate session. The same volume of hypertonic or isotonic saline was injected into the control site as designated by the randomisation. Participants and injector were blinded to saline type administered. All injections were given by an orthopaedic surgeon (MI). After a standard disinfection protocol, the injections were given over the duration of approximately 10 seconds using a 2-ml plastic syringe with a disposable needle (27G). Pre-defined anatomical landmarks for injection sites for AL and RF tendons were utilised. The location, depth and alignment of all injection sites were confirmed by real time

ultrasound (US) imaging (*Acuson 128XP10, NativeTM*). The AL tendon was identified using a method previously described.<sup>18</sup> Both the AL and RF injections positions followed a previously published protocol (Supplement 1).<sup>20</sup>

The pain intensity produced by hypertonic saline injections was assessed on a 10 cm electronic visual analogue scale (VAS) which could be adjusted by using an external handheld slider. The VAS was anchored with ‘no pain’ and ‘maximum pain’, 0 cm and 10 cm, respectively. A continuous recording (sample frequency of 20 Hz) of the VAS signal was made after each injection until all pain had subsided. For analysis, the area under VAS-time curve (VAS area) and VAS-peak were extracted.

The quality of pain was assessed once the pain had subsided. Participants were allowed to answer using either the Danish<sup>21</sup> or English<sup>22</sup> version of the McGill Pain Questionnaire based upon their language preference. The Danish results were converted to the English equivalent for analysis. Participants were asked to mark their pain distribution by filling in a standard body chart. Body areas were divided into groin regions by using the “Groin Triangle”.<sup>23</sup> The groin triangle is defined as the triangle created by the three landmarks: the anterior superior iliac spine (ASIS), pubic tubercle and the median point between the ASIS and the superior pole of the patella in the anterior coronal plane (‘3G point’).<sup>24</sup> Local pain was defined as pain experienced only at the injection site and related “Groin Triangle” segment while referred pain was defined as any pain felt outside the segment containing the injection site. The body regions were analysed by registering the frequency of pain experienced in the region for all four injections.

Pressure pain thresholds (PPTs) were assessed at regional and distant sites using a handheld pressure algometer (*Somedic, Sweden*) with a 1 cm<sup>2</sup> probe and using a 30 kPa/s ramp. The four bilateral assessment sites were the AL tendon injection site, the RF tendon injection site, the anterior surface of the superior pubic rami (PB), and the tibialis anterior (TA) muscle, measured as the proximal site 1/3 the distance from the lateral joint line of the knee to the inferior aspect of the lateral malleolus. Each



measurement was recorded three times at baseline with two measurements recorded during pain and post-pain to ensure all testing could be completed within the short-lasting window of saline-induced pain. The average of the measurements was used for statistical analysis. PPT measurement was ceased at 1200 kPa to avoid sensitisation after repeated assessments.

A battery of six pain provocation tests (Supplement 2) was employed with all tests performed by a single clinically-trained experimenter (MD). All participants were confirmed to be pain-free on all tests prior commencing the study. The tests administered were as previously published:<sup>20</sup> 1) Bilateral adduction (squeeze) test with hips at 0° resisted at the ankles<sup>25</sup> 2) A bilateral squeeze test<sup>11</sup> with hips flexed at 45° 3) A bilateral squeeze test<sup>11</sup> with hips flexed to 90° 4) Resisted abdominal crunch<sup>25</sup> 5) Resisted oblique crunch, one side at a time.<sup>25</sup> The force of contraction was measured using a hand-held dynamometer (*MicroFET2, Hoggan Health Industries, USA*) at baseline, during-pain and post-pain. The reliability of the 0° adduction test is high (ICC = 0.97, minimal detectable change (%) = 6.6).<sup>26</sup> Verbal encouragement by the assessor was given to ensure force output remained constant for each repetition (within 10% of baseline measures).

The skin at each assessment site was shaved, abraded and cleaned with alcohol in accordance with the SENIAM guidelines.<sup>27</sup> Disposable electrodes (*Ambu®, Neuroline 720, Denmark*) were mounted bilaterally with an inter-electrode distance of 20 mm in a bipolar configuration at the m. tensor fasciae latae (TFL), the m. adductor longus (AL), m. rectus abdominis (RA), and m. external obliques (EO).<sup>11</sup>

<sup>28</sup> A ground electrode was placed on the right wrist. The EMG signal from the AL muscle was used as reference to determine the time window for the amplitude analysis (from onset to offset)<sup>29</sup> where the root-mean-square (RMS) value was extracted for all muscles during all six tests for the middle epoch defined as middle third of the period between onset and offset (see Supplement 1 for extended methodology). The RMS value represents the muscle activity of the muscle. The onsets and offsets were automatically detected based on the AL muscle EMG data as previously described in detail by Santello et al.<sup>29</sup> All onset/offset detections were confirmed by visual inspection at each time point. No

manual correction of the data was required. Onsets and offsets were not analysed as the research question investigated related to maximal muscle activity pre-, during and post-experimental pain conditions rather than changes in the order of activation as a result of pain. Filtered EMG data was utilised for analysis however filter and normalised data to baseline measures is reported in the supplements for the ease of interpretation clinically.

All data was assessed for normality using the Kolmogorov–Smirnov test. Means and standard deviations (SD) are presented for parametric data. All statistical analyses were performed using Stata 13 IC unless indicated (*StataCorp, USA*). An *a priori* estimate of group size indicated 15 participants were required (estimated 20% difference in effect parameters;  $\alpha=5\%$ ;  $\beta=20\%$ ; coefficient of variance=25%). The VAS area was analysed with an analysis of variance (ANOVA) with muscle (*AL and RF*) and injection (*hypertonic and isotonic*) as independent factors. To assess the relationship of PPTs and the injection site, side and injection type, a linear mixed-effect model (restricted maximum likelihood [REML] regression) was fitted with PPT site (*AL, pubic bone, RF, and tibialis anterior*), injection type (*hypertonic and isotonic*), side (ipsi- or contralateral) and injection site (*RF and AL*) and time (*baseline, during or post*) and their interactions as fixed-effects. For analysis, filtered EMG data was utilised to assess the relationship between mean RMS-EMG of each clinical test and the effects of injection type (*isotonic and hypertonic*), time point (*baseline, during, post-pain*), each muscle (*AL, TFL, EO, RA*), injection site (*AL and RF*) and side (*ipsilateral and contralateral*) and their interactions with a random effect for participant in a General Linear Mixed Model using the R package lme4 (R Core Team, 2016).<sup>30</sup> This approach can handle missing data which created an unbalanced design.<sup>31</sup> Means were analysed *post-hoc* to explain significant effects. Bonferroni correction was applied where multiple *post-hoc* analyses were undertaken. Significance was set at  $p<0.05$  for all statistical tests.

## Results

The VAS area after hypertonic saline injected into the AL ( $13112 \pm 11147$  mm·s) and RF ( $12110 \pm 8829$  mm·s) tendons were higher compared with isotonic saline (AL:  $206 \pm 405$  mm·s; RF:  $815 \pm 2037$  mm·s; ANOVA:  $F(2,53)=20.05$ ,  $p<0.001$ ). The VAS-peaks reported for each test condition were AL isotonic ( $2 \pm 4$ mm), AL hypertonic ( $22 \pm 12$  mm), RF isotonic ( $4 \pm 7$  mm), and RF hypertonic ( $22 \pm 12$  mm). The three most common words to describe the sensation after the AL tendon hypertonic injections were “annoying” (33% of participants), “tugging” (27%) and “pressing” (27%) whereas the three most common descriptions after the RF tendon hypertonic injections “tight” (47%), “pressing” (33%), “annoying” (27%) for RF tendon.

Hypertonic saline-induced pain in the AL tendon primarily demonstrated a local pattern of pain where it was mainly perceived within and medial to the “Groin Triangle” but also in the lower abdominal region (Figure 1, Table 1). Injections of hypertonic saline into the RF tendon primarily caused pain experienced within the triangle and the anterior and lateral thigh indicating a larger pain referral pattern. During isotonic saline injections into the RF tendon, 11 participants drew the pain on the anterior thigh. Pain in the contralateral side to the injection was also reported in one participant in three areas (Supplementary 3) after the hypertonic injection into the RF tendon. No participants reported pain on the contralateral side with an absence of pain in the ipsilateral injection side. Therefore, these reports should be considered as bilateral pain distributions.

PPT values did not significantly change across time periods under any conditions. Significant fixed effects were observed for the RF (REML: Coeff=362.5, 95%CI 265.8-564.2,  $p<0.001$ ) and TA sites (REML: Coeff=469.8, 95%CI 374.8-561.8,  $p<0.001$ ) indicating that the TA and RF sites were generally higher than the adductor and pubic sites. However, no significant fixed effects or interactions were observed with the inclusion of time ( $p=0.27-0.99$ ). As time was not a significant fixed effect, this can be interpreted as the PPT values were not significantly influenced by experimental pain conditions. The distributions of PPT values across the experimental conditions and time points are presented in Figure 2.

The magnitude of the muscle activity did not change significantly across time periods under any conditions when compared to baseline conditions. Normalised RMS-EMG for the “during” and “post” conditions are presented in Supplementary Tables 1-4. A five-way interaction between clinical test, injection type, muscle, injection site and side was observed ( $F(15,7771)=8.68$ ,  $p<0.001$ ) however time was not a significant fixed effect in the model or any interactions. As time was not a significant fixed effect it can be interpreted as the muscle activation patterns of the four muscles varied across the clinical tests, injection type and site, and side when compared to each other yet were not significantly uninfluenced by the experimental pain. Therefore, no *post-hoc* analyses were performed.

## Discussion

This is the first study to report the muscle activation pattern involved in commonly used clinical tests for groin pain and mechanical sensitivity of the lower limb in an experimental pain model. This study aimed to examine three hypotheses surrounding experimental pain at the proximal insertion of the adductor longus. The results of this study support the hypothesis that experimental pain in the proximal adductor longus can proximally refer to the lower abdomen and may explain why pain can be experienced in both locations clinically. This study fails to provide evidence that experimental pain in the AL alters the muscle activity and produces local or widespread deep tissue hyperalgesia. These findings have implications for clinical assessment particularly related to diagnostic or classification criteria which rely on pain referral patterns as they can be influenced by region structures.

The AL tendon produced a local pain distribution contained mainly medial to and within the “Groin Triangle”. Moreover, in 33% of participants the tendon of adductor longus was capable of provoking proximal referral into the lower abdominal region. This has clinical relevance as it is commonly reported in the literature that multiple pathologies or clinical entities exist in athletes with groin pain.<sup>5</sup> Experimentally-induced AL tendon pain is capable of producing false positive test results with abdominal manoeuvres.<sup>20</sup> Therefore, comprehensive clinical assessment is required to rule out

involvement of AL tendon when pain in the lower abdomen is present particularly when coexisting with pain in the upper inner thigh. The results of experimental pain models<sup>20</sup> indicate that 45° and 90° adduction tests have the best negative likelihood ratio, suggesting their utility to rule out adductor longus as a potential source of nociception. The positive control condition (experimental RF tendon pain) produced a greater distribution of pain covering the regions within, lateral to and superior to the groin triangle although no pain was reported medial to the triangle. Bilateral leg pain distribution was produced in one participant under the RF tendon hypertonic and isotonic saline conditions. This represents an unusual pain referral pattern that is not typically observed clinically and may be related to individual characteristics of the participant.

In the present study, pain induced in adductor and thigh regions was unable to alter the mechanical sensitivity. Primary mechanical hyperalgesia of the adductor longus tendon has been reported in Australian football players currently experiencing groin pain.<sup>1</sup> This indicates the hypertonic saline tendon pain model may not replicate the clinical pain presentations of groin region. Proximal (secondary) hyperalgesia has been hypothesised to be explained by amplification of central pain mechanisms.<sup>32</sup> No change was observed at the pubic bone or distally on either sides which concurs with clinical pain studies of the groin region.<sup>1</sup> The diagnostic criteria for adductor-related groin pain are pain on resisted adduction tests with tenderness (mechanical sensitivity) on palpation.<sup>4</sup> In acute groin injuries, palpation (mechanical sensitivity) has the greatest diagnostic capacity to predict MRI findings.<sup>33</sup> In the present study, no changes were observed at the site of the injection or on the pubic bone PTTs under the AL or RF ipsilateral hypertonic saline-induced pain indicating secondary mechanical hyperalgesia is less of a concern for this site. Therefore, hyperalgesia of the pubic bone may represent local mechanical hyperalgesia rather than regional/widespread pain and as such may be implicated as a nociceptive driver. Clinically, mechanical sensitivity (tenderness on palpation) at the pubic enthesis may represent local nociception rather than a consequence of adductor tendon pain (as in the case of secondary hyperalgesia). Confirmation in the clinical setting is warranted however.

The magnitude of muscle activity in the region during the painful condition was not statistically significantly different from the baseline condition. This is hypothesised to be due to the study design in which force was maintained equal to baseline measures. This indicates that irrespective of pain in the region, the motor cortex may allow for the task to be completed with equal force production. The 0° adduction test has been suggested to be diagnostically superior to identify experimentally-induced, adductor-related pain.<sup>20</sup> However, the results of this paper indicate that changes in muscle activation less likely to be associated with the diagnostic capabilities reported. Again, this hypothesis should be tested in clinical populations.

This study allowed the evaluation of the outcome measures under controlled conditions. This removes the complications of multiple pathologies detected on clinical assessment<sup>5</sup> and imaging<sup>8</sup> in athletes with groin pain. Nonetheless, pain generated from experimental models differs from clinical pain<sup>18</sup> and replication of the results in clinical populations is warranted as previously indicated. In the analysis of PPT and EMG data, a unified linear mixed model was chosen given its ability to account for the characteristics of the data and to reduce the Type I error associated with multiple sub-grouping analyses. The lack of positive findings observed may be potentially explained by lower power however this is offset by the degrees of freedom created by every participant undertaking each component of the study. Significant variability in the data was observed in the PPT and the level of pain (VAS) measures across participants. This variability reduced the ability to obtain significant effects; an increase in sample size is unlikely to alter the results and are likely to represent the individual nature of the response to pain. *Post-hoc* power analyses are therefore not indicated.<sup>34</sup>

## Conclusion

This study has shown that pain arising from the adductor longus tendon is locally distributed in the majority (80%) but capable of producing pain superior to the pubic crest in 33% of participants. PPTs were not altered by experimental pain induced by hypertonic saline. An alteration of the magnitude of EMG activity of the adductor longus, tensor fascia latae, rectus abdominis and external obliques was

296 not detected under experimental pain conditions when force was matched to baseline measures.  
297 Therefore, diagnostic criteria based on pain distribution alone may be influenced by pain itself in the  
298 region and may not represent tissue pathology or multiple clinical entities of groin pain.

299

300

301

## **Practical Implications**

- The adductor longus tendon has a local pattern of pain distribution however can refer proximally to the lower abdominal region.
- Diagnostic criteria based on pain distribution are potentially influenced by pain itself in the region and may not represent tissue pathology.

## **Acknowledgements**

The authors would like to thank Dr XXX XXXX and Prof. XXX XXXX for their assistance with the statistical analyses. This study received (non-grant) funding from the University of XXX and the XXX.

## **Conflict of interest**

There are no conflicts of interest of the authors.



315 **References**

- 316 1. Drew MK, Palsson TS, Lovell G, Chiarelli PE, Osmotherly PG. Do Australian Football  
317 players have sensitive groins? Players with current groin pain exhibit mechanical hyperalgesia  
318 of the adductor tendon. *J. Sci. Med. Sport.* 2016; 19(10):784-788.
- 319 2. Werner J, Hägglund M, Walden M, Ekstrand J. UEFA injury study: a prospective study of hip  
320 and groin injuries in professional football over seven consecutive seasons. *Br. J. Sports Med.*  
321 2009; 43(1):1036-1040.
- 322 3. Dalton SL, Zupon AB, Gardner EC, Djoko A, Dompier TP, Kerr ZY. The Epidemiology of  
323 Hip/Groin Injuries in National Collegiate Athletic Association Men's and Women's Ice  
324 Hockey. *Orthopaedic Journal of Sports Medicine.* 2016; 4(3):2325967116632692.
- 325 4. Weir A, Brukner P, Delahunt E, et al. Doha agreement meeting on terminology and  
326 definitions in groin pain in athletes. *Br. J. Sports Med.* 2015; 49(12):768-774.
- 327 5. Holmich P. Long-standing groin pain in sportspeople falls into three primary patterns, a  
328 "clinical entity" approach: a prospective study of 207 patients. *Br. J. Sports Med.* 2007;  
329 41(4):247-252.
- 330 6. Graven-Nielsen T. Fundamentals of muscle pain, referred pain, and deep tissue hyperalgesia.  
331 *Scand. J. Rheumatol. Suppl.* 2006; 122:1-43.
- 332 7. Hölmich P, Thorborg K, Dehlendorff C, Krogsgaard K, Gluud C. Incidence and clinical  
333 presentation of groin injuries in sub-elite male soccer. *Br. J. Sports Med.* 2014; 48(16):1245-  
334 1250.
- 335 8. Branci S, Thorborg K, Bech BH, Boesen M, Nielsen MB, Hölmich P. MRI findings in soccer  
336 players with long-standing adductor-related groin pain and asymptomatic controls. *Br. J.*  
337 *Sports Med.* 2014; 49(10):681-691.
- 338 9. Branci S, Thorborg K, Nielsen MB, Holmich P. Radiological findings in symphyseal and  
339 adductor-related groin pain in athletes: a critical review of the literature. *Br. J. Sports Med.*  
340 2013; 47(10):611-619.
- 341 10. Weir A, de Vos RJ, Moen M, Holmich P, Tol JL. Prevalence of radiological signs of  
342 femoroacetabular impingement in patients presenting with long-standing adductor-related  
343 groin pain. *Br. J. Sports Med.* 2011; 45(1):6-9.
- 344 11. Lovell GA, Blanch PD, Barnes CJ. EMG of the hip adductor muscles in six clinical  
345 examination tests. *Phys Ther Sport.* 2012; 13(2):134-140.
- 346 12. Jansen JA, Poot B, Mens JMA, Backx FJG, Stam HJ. The Effect of Experimental Groin Pain  
347 on Abdominal Muscle Thickness. *Clin. J. Pain.* 2010; 26(4):300-305.
- 348 13. Cagnie B, Dirks R, Schouten M, Parlevliet T, Cambier D, Danneels L. Functional  
349 reorganization of cervical flexor activity because of induced muscle pain evaluated by muscle  
350 functional magnetic resonance imaging. *Man Ther.* 2011; 16(5):470-475.
- 351 14. Falla D, Farina D, Graven-Nielsen T. Experimental muscle pain results in reorganization of  
352 coordination among trapezius muscle subdivisions during repetitive shoulder flexion. *Exp.*  
353 *Brain Res.* 2007; 178(3):385-393.
- 354 15. Graven-Nielsen T, Arendt-Nielsen L. Impact of clinical and experimental pain on muscle  
355 strength and activity. *Curr Rheumatol Rep.* 2008; 10(6):475-481.
- 356 16. Palsson TS, Hirata RP, Graven-Nielsen T. Experimental Pelvic Pain Impairs the Performance  
357 During the Active Straight Leg Raise Test and Causes Excessive Muscle Stabilization. *Clin.*  
358 *J. Pain.* 2015; 31(7):642-651.
- 359 17. Arendt-Nielsen L, Graven-Nielsen T, Sværre H, Svensson P. The influence of low back pain  
360 on muscle activity and coordination during gait: a clinical and experimental study. *Pain.*  
361 1996; 64(2):231-240.
- 362 18. Izumi M, Petersen KK, Arendt-Nielsen L, Graven-Nielsen T. Pain referral and regional deep  
363 tissue hyperalgesia In experimental human hip pain models. *Pain.* 2014; 155(4):792-800.
- 364 19. Palsson TS, Graven-Nielsen T. Experimental pelvic pain facilitates pain provocation tests and  
365 causes regional hyperalgesia. *Pain.* 2012; 153(11):2233-2240.

20. Drew MK, Palsson TS, Izumi M, et al. Resisted adduction in hip neutral is a superior provocation test to assess adductor longus pain: An experimental pain study. *Scand. J. Med. Sci. Sports.* 2016; 26(8):967-974.
21. Drewes AM, Helweg-Larsen S, Petersen P, et al. McGill Pain Questionnaire translated into Danish: experimental and clinical findings. *Clin. J. Pain.* 1993; 9(2):80-87.
22. Melzock R, Torgerson W. On the language of pain. *Anesthesiology.* 1971; 34(1):50-59.
23. Falvey EC, Franklin-Miller A, McCrory PR. The groin triangle: a patho-anatomical approach to the diagnosis of chronic groin pain in athletes. *Br. J. Sports Med.* 2008; 43(3):213-220.
24. Franklin-Miller A, Falvey E, McCrory P. Landmarks for the 3G approach: groin, gluteal, and greater trochanter triangles, a pathoanatomical method in sports medicine. *Eur J Anat.* 2008; 12(1):81-87.
25. Holmich P, Holmich LR, Bjerg AM. Clinical examination of athletes with groin pain: an intraobserver and interobserver reliability study. *Br. J. Sports Med.* 2004; 38(4):446-451.
26. Light N, Thorborg K. The precision and torque production of common hip adductor squeeze tests used in elite football. *J. Sci. Med. Sport.* 2015.
27. Hermens HJ, Freriks B, Merletti R, et al. SENIAM 8: European Recommendations for Surface ElectroMyoGraphy: Roessingh Research and Development 1999.
28. Hu H, Meijer OG, Van Dieen JH, et al. Muscle activity during the active straight leg raise (ASLR), and the effects of a pelvic belt on the ASLR and on treadmill walking. *J. Biomech.* 2010; 43(3):532-539.
29. Santello M, McDonagh M. The control of timing and amplitude of EMG activity in landing movements in humans. *Exp. Physiol.* 1998; 83(6):857-874.
30. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. 2015. 2015; 67(1):48.
31. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. *Biometrics.* 1986:805-820.
32. Schaible HG. Basic mechanisms of deep somatic tissue, in *Textbook of Pain*. McMahon SB, Koltzenburg M, eds. Philadelphia, Elsevier/Churchill Livingstone, 2006.
33. Serner A, Weir A, Tol JL, et al. Can standardised clinical examination of athletes with acute groin injuries predict the presence and location of MRI findings? *Br. J. Sports Med.* 2016.
34. Hoenig JM, Heisey DM. The abuse of power. *The American Statistician.* 2012.

## TABLES

**Table 1** Frequency of pain relative to the “Groin Triangle” following injections of hypertonic and isotonic saline into the adductor longus and rectus femoris tendons.

|                           | Adductor Longus Tendon |               |                   |               | Rectus Femoris Tendon |               |                   |               |
|---------------------------|------------------------|---------------|-------------------|---------------|-----------------------|---------------|-------------------|---------------|
|                           | Isotonic saline        |               | Hypertonic saline |               | Isotonic saline       |               | Hypertonic saline |               |
|                           | Ipsilateral            | Contralateral | Ipsilateral       | Contralateral | Ipsilateral           | Contralateral | Ipsilateral       | Contralateral |
| <b>“Groin Triangle”</b>   |                        |               |                   |               |                       |               |                   |               |
| Within the triangle       | 3 (20)                 | 0             | 12 (80 %)         | 0             | 4 (27%)               | 1 (7%)        | 15 (100%)         | 2 (13%)       |
| Lateral to the triangle   | 0                      | 0             | 1 (7 %)           | 0             | 0                     | 0             | 2 (13%)           | 0             |
| Medial to the triangle    | 7 (47)                 | 0             | 12 (80%)          | 0             | 0                     | 0             | 0                 | 0             |
| Superior to the triangle  | 0                      | 0             | 5 (33 %)          | 0             | 0                     | 0             | 1 (7%)            | 0             |
| <b><i>Other areas</i></b> |                        |               |                   |               |                       |               |                   |               |
| Greater Trochanter        | 0                      | 0             | 0                 | 0             | 0                     | 0             | 0                 | 2 (13%)       |
| Anterior Thigh            | 0                      | 0             | 1 (7 %)           | 0             | 2 (13%)               | 0             | 5 (33%)           | 2 (13%)       |
| Lateral Thigh             | 0                      | 0             | 0                 | 0             | 0                     | 0             | 4 (27%)           | 1 (7%)        |
| Knee                      | 0                      | 0             | 0                 | 0             | 0                     | 0             | 0                 | 1 (7%)        |
| Lower Leg                 | 0                      | 0             | 0                 | 0             | 0                     | 0             | 1 (7%)            | 2 (13%)       |
| Foot                      | 0                      | 0             | 0                 | 0             | 0                     | 0             | 0                 | 0             |

Contralateral/Ipsilateral relative to the side of injection; frequencies reported as number of responses (percentage)

## **FIGURE LEGENDS**


**Figure 1** Pain distributions of the adductor longus are indicated on the body chart's right side.

**Figure 2** Distribution of the pressure pain thresholds at baseline, during pain and post-pain across injection types and sites represented as a box-plot.

Figure 1  
[Click here to download high resolution image](#)



**Figure 2**  
[Click here to download high resolution image](#)



## Supplement 1 – Extended methodology

### Injection position

The AL tendon was identified using a method previously described.<sup>13</sup> The participant lay supine with the leg to be injected supported in a slightly abducted, flexed position (figure four position) with the heel resting on the knee on the contralateral side. The injection site was along the midline of the tendon, 1 cm from the pubic bone. The skin was marked and AL tendon position was confirmed by resisting hip adduction under ultrasound imaging.

The RF tendon was found by manual palpation below its attachment to the anterior inferior iliac spine and was followed distally towards the musculotendinous junction. The injection site was defined as the centre of the tendon of the long head of the rectus femoris muscle. The location and depth of the injection was confirmed by the performance of hip flexion against resistance while under ultrasound observation. The injection site was marked after confirmation.

### Electromyographic placement, sampling and data extraction

The skin at each assessment site was shaved, abraded and cleaned with alcohol in accordance with the SENIAM guidelines.<sup>20</sup> Disposable electrodes (*Ambu®*, *Neuroline 720*, *Denmark*) were mounted bilaterally with an inter-electrode distance of 20 mm in a bipolar configuration at the m. tensor fascia latae (TFL), the m. adductor longus (AL), m. rectus abdominis (RA), and m. external obliques (EO).<sup>6,21</sup> A ground electrode was placed on the right wrist. All electrodes were secured by tape (*Micropore™ Surgical Tape*, *3M™*, *USA*). The electromyographic (EMG) signals were sampled at 2048 Hz with a gain of 2000 using a 128-channel surface EMG amplifier (*WSI OT Bioelettronica*, *Italy*) and converted to digital form by a 12-bit analogue-to-digital converter (*LISiN-OT Bioelettronica*, *Torino*, *Italy*; -3 dB bandwidth 10-500 Hz). The digitized EMG signals were band-pass filtered (4th order, zero-phase-lag Butterworth, 25 to 450 Hz). The EMG signal from the AL muscle was used as reference to determine the time window for the amplitude analysis (from onset to offset)<sup>22</sup> where the root-mean-square (RMS) value was extracted for all muscles for the middle epoch

defined as middle third of the period between onset and offset. The onsets and offsets were automatically detected based on the AL muscle EMG data as previously described in detail by Santello et al.<sup>22</sup> In short, the accumulated integrated EMG (iEMG) was normalized to 1 in both amplitude and time and subtracted by a reference line with slope equal to 1. The time point where this difference was larger was defined as the muscle activity onset. Similar approach was used for the offset activity. All onset/offset detections were confirmed by visual inspection at each time point (baseline, during pain, post-pain). No manual correction of the data was required.



## Supplement 2 – Clinical tests



(a) The 0° adduction test: The participant lay with legs straight and the examiner placed the forearm between the medial malleoli with the dynamometer fixed to one end, the participant was instructed to adduct maximally. (b) The 45° adduction test: The participant lay with the feet flat on the plinth with hips flexed to 45° and the knees at 90° of flexion and performed maximal adduction with the dynamometer held in place by the examiner between the medial condyles of the knees. (c) The 90° adduction test: the participant lay with the hips and knees at 90° of flexion and performed maximal adduction with the dynamometer between the medial femoral condyles. (d) The abdominal crunch manoeuvre: the participant performed maximal trunk flexion with the hips and knees in the same position as the 45° test. The dynamometer was placed on the sternum where the examiner applied resistance to the movement. (e) The oblique crunch manoeuvre: the dynamometer was positioned on the shoulder contralateral to the examiner who applied resistance while the participant performed an abdominal crunch towards the contralateral knee.

### Supplement 3 – Pain distribution for the control injections



Adductor Longus - Isotonic



Rectus Femoris - Hypertonic



Rectus Femoris - Isotonic

**Supplementary Table 1.** Mean normalised RMG-EMG [95%CI] during the clinical tests after experimentally-induced groin (AL hypertonic injections) and thigh pain (RF hypertonic injections). The RMS-EMG is normalised to baseline (100%).

| Injection                     | Test position                            | Adductor longus         |                        | Tensor fascia latae     |                       | Rectus abdominis        |                         | External oblique        |                         |
|-------------------------------|--|-------------------------|------------------------|-------------------------|-----------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                               |  | Ipsilateral             | Contralateral          | Ipsilateral             | Contralateral         | Ipsilateral             | Contralateral           | Ipsilateral             | Contralateral           |
| AL<br>Hypertonic<br>Injection | 0° adduction                             | 84.6<br>[72.4, 96.7]    | 90.3<br>[75.88,104.65] | 99.1<br>[78.3,119.9]    | 102.8<br>[85.5,120.2] | 111.7<br>[88.8,134.6]   | 121.8<br>[94.5,149.0]   | 116.2<br>[90.9,141.4]   | 126.2<br>[96.6,155.9]   |
|                               | 45° adduction                            | 92.0<br>[80.3,103.8]    | 92.3<br>[81.1,102.6]   | 97.1<br>[65.3,128.8]    | 95.6<br>[70.1,121.1]  | 116.3<br>[97.1,135.5]   | 109.85<br>[81.9,137.8]  | 118.9<br>[95.8,142.0]   | 121.0<br>[103.3,138.7]  |
|                               | 90° adduction                            | 104.6<br>[92.5,116.7]   | 116.7<br>[92.8,140.7]  | 108.3<br>[92.9,123.8]   | 126.5<br>[93.4,159.7] | 119.3<br>[106.9, 131.7] | 118.2<br>[106.0, 130.3] | 113.4<br>[83.5,143.3]   | 125.3<br>[95.0,155.6]   |
|                               | Resisted abdominal<br>crunch             | 106.4<br>[92.8,120.0]   | 108.7<br>[91.7,125.7]  | 161.3<br>[104.7,217.8]  | 115.6<br>[99.8,131.3] | 116.1<br>[101.1,131.1]  | 102.9<br>[93.2,112.6]   | 98.0<br>[77.6,118.4]    | 98.4<br>[82.7,114.1]    |
|                               | Ipsilateral Resisted<br>oblique crunch   | 95.6<br>[81.3,109.8]    | 98.8<br>[88.9,108.7]   | 105.3<br>[73.7,137.0]   | 103.1<br>[93.9,112.4] | 115.9<br>[85.8,146.0]   | 107.4<br>[95.7,119.2]   | 99.9<br>[82.5,117.3]    | 102.8<br>[84.3,121.4]   |
|                               | Contralateral Resisted<br>oblique crunch | 102.2<br>[92.0,112.5]   | 111.2<br>[81.8,140.6]  | 121.5<br>[82.9,160.2]   | 107.8<br>[87.0,128.7] | 116.3<br>[83.7,148.8]   | 93.7<br>[78.0,109.4]    | 96.1<br>[84.3,107.8]    | 99.9<br>[86.6,113.2]    |
| RF<br>Hypertonic<br>Injection | 0° adduction                             | 105.8<br>[92.5,119.0]   | 107.7<br>[95.6,119.7]  | 112.8<br>[94.3,131.3]   | 107.9<br>[94.6,121.2] | 191.3<br>[31.4,351.2]   | 152.8<br>[71.1,234.5]   | 123.9<br>[104.3, 143.4] | 120.6<br>[101.4, 139.8] |
|                               | 45° adduction                            | 94.4<br>[86.4,102.4]    | 96.4<br>[87.9,105.0]   | 84.1<br>[65.0,103.3]    | 100.6<br>[77.9,123.3] | 111.1<br>[81.8,140.4]   | 110.9<br>[85.2,136.6]   | 104.6<br>[81.5,127.8]   | 105.0<br>[83.0,127.1]   |
|                               | 90° adduction                            | 106.8<br>[91.3,122.3]   | 108.9<br>[95.8,122.1]  | 125.3<br>[102.7, 147.9] | 111.7<br>[92.8,130.7] | 108.7<br>[92.8,124.7]   | 111.1<br>[92.5,129.7]   | 109.6<br>[95.8,123.4]   | 104.8<br>[91.0,118.6]   |
|                               | Resisted abdominal<br>crunch             | 113.3<br>[103.1, 123.5] | 111.3<br>[93.2,129.5]  | 114.3<br>[90.0,144.7]   | 108.7<br>[82.1,135.3] | 105.3<br>[95.3,115.3]   | 108.0<br>[98.4,117.6]   | 102.6<br>[75.5,129.7]   | 101.5<br>[81.2, 121.8]  |
|                               | Ipsilateral Resisted<br>oblique crunch   | 105.3<br>[92.7,117.9]   | 105.9<br>[85.6,126.3]  | 140.0<br>[72.3,207.7]   | 103.4<br>[88.9,117.8] | 111.0<br>[98.6,123.5]   | 113.5<br>[100.3, 126.7] | 116.0<br>[98.5,133.5]   | 116.3<br>[100.4,132.2]  |
|                               | Contralateral Resisted<br>oblique crunch | 91.2<br>[76.2,106.3]    | 97.4<br>[67.9,127.0]   | 89.2<br>[67.8,110.6]    | 83.4<br>[65.7,101.1]  | 102.4<br>[87.5,117.2]   | 106.2<br>[87.9,124.6]   | 96.7<br>[79.0,114.4]    | 99.9<br>[74.5,125.3]    |

**Supplementary Table 2.** Mean normalised RMG-EMG [95%CI] during the clinical tests after control injections into the groin (AL isotonic injections) and thigh (RF isotonic injections). The RMS-EMG is normalised to baseline (100%).

| Injection                   | Test position                            | Adductor longus       |                       | Tensor fascia latae   |                       | Rectus abdominis      |                        | External oblique      |                       |
|-----------------------------|--|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|------------------------|-----------------------|-----------------------|
|                             |  | Ipsilateral           | Contralateral         | Ipsilateral           | Contralateral         | Ipsilateral           | Contralateral          | Ipsilateral           | Contralateral         |
| AL<br>Isotonic<br>Injection | 0° adduction                             | 96.5<br>[87.1,106.0]  | 95.3<br>[86.3,104.3]  | 137.6<br>[52.5,222.6] | 113.5<br>[78.5,148.4] | 122.3<br>[90.9,153.6] | 142.9<br>[83.6,202.3]  | 108.8<br>[89.4,128.2] | 106.0<br>[87.1,124.9] |
|                             | 45° adduction                            | 108.6<br>[96.8,120.4] | 109.4<br>[95.3,123.6] | 111.3<br>[92.2,130.4] | 129.1<br>[97.1,161.1] | 128.7<br>[89.4,167.9] | 280.5<br>[-77.9,638.9] | 113.4<br>[95.0,131.8] | 128.5<br>[99.9,157.1] |
|                             | 90° adduction                            | 103.6<br>[90.0,117.3] | 101.4<br>[88.1,114.6] | 97.2<br>[77.7,116.6]  | 99.3<br>[84.2,114.5]  | 120.8<br>[56.7,185.0] | 162.7<br>[120.0,313.3] | 109.5<br>[93.5,125.4] | 111.4<br>[91.2,131.6] |
|                             | Resisted abdominal<br>crunch             | 116.9<br>[98.2,137.6] | 100.5<br>[85.8,115.2] | 100.0<br>[83.5,116.4] | 97.9<br>[83.0,112.8]  | 105.2<br>[95.9,114.5] | 106.3<br>[80.1,132.5]  | 91.3<br>[82.2,100.3]  | 96.8<br>[81.0,112.6]  |
|                             | Ipsilateral Resisted<br>oblique crunch   | 106.7<br>[88.8,124.6] | 105.7<br>[94.8,116.6] | 108.9<br>[90.4,127.4] | 119.2<br>[88.2,150.1] | 101.6<br>[86.3,116.9] | 112.8<br>[86.5,139.0]  | 93.3<br>[82.1,104.5]  | 90.7<br>[78.8,102.6]  |
|                             | Contralateral Resisted<br>oblique crunch | 106.9<br>[94.8,118.9] | 110.5<br>[90.6,130.5] | 101.7<br>[87.7,115.7] | 117.1<br>[94.7,139.5] | 114.8<br>[91.1,138.5] | 139.6<br>[88.9,190.4]  | 103.1<br>[91.8,114.3] | 100.0<br>[86.4,113.6] |
| RF<br>Isotonic<br>Injection | 0° adduction                             | 105.0<br>[91.8,118.2] | 102.4<br>[90.7,114.2] | 132.9<br>[64.2,201.5] | 140.7<br>[60.0,221.4] | 115.9<br>[91.1,140.8] | 110.2<br>[85.7,134.6]  | 109.3<br>[85.0,133.7] | 108.8<br>[84.8,132.8] |
|                             | 45° adduction                            | 102.1<br>[92.1,112.2] | 103.6<br>[94.4,112.8] | 104.8<br>[84.3,125.4] | 132.1<br>[76.6,187.5] | 98.4<br>[87.2,109.7]  | 102.7<br>[92.5,113.0]  | 110.9<br>[87.3,134.4] | 110.1<br>[85.0,135.3] |
|                             | 90° adduction                            | 106.7<br>[92.7,120.6] | 104.5<br>[91.1,117.9] | 133.0<br>[81.3,184.6] | 106.1<br>[87.6,124.7] | 91.9<br>[67.7,116.2]  | 93.8<br>[65.9,121.6]   | 96.2<br>[78.4,114.1]  | 92.4<br>[78.5,106.4]  |
|                             | Resisted abdominal<br>crunch             | 102.3<br>[92.3,112.3] | 107.3<br>[88.3,126.4] | 101.8<br>[77.1,126.5] | 111.2<br>[95.1,127.4] | 89.1<br>[76.9,101.3]  | 90.0<br>[78.0,101.9]   | 93.4<br>[81.5,105.4]  | 88.8<br>[74.0,103.6]  |
|                             | Ipsilateral Resisted<br>oblique crunch   | 120.1<br>[98.3,141.8] | 124.2<br>[93.7,154.7] | 124.0<br>[84.2,163.8] | 111.7<br>[86.8,136.7] | 109.3<br>[82.6,136.0] | 105.8<br>[81.6,130.1]  | 110.5<br>[90.5,130.5] | 110.8<br>[86.8,134.9] |
|                             | Contralateral Resisted<br>oblique crunch | 110.5<br>[92.8,128.2] | 108.4<br>[88.2,128.5] | 105.4<br>[92.1,118.7] | 102.0<br>[88.2,115.9] | 100.6<br>[85.7,115.5] | 99.3<br>[84.8,113.9]   | 100.7<br>[91.3,110.2] | 99.8<br>[90.6,108.9]  |

**Supplementary Table 3.** Mean normalised RMG-EMG [95%CI] during the clinical tests in the post-pain condition after experimentally-induced groin (AL hypertonic injections) and thigh pain (RF hypertonic injections) had resolved. The RMS-EMG is normalised to baseline (100%).

| Injection                     | Test position                            | Adductor longus<br>mean (%), [95% CI] |                       | Tensor fascia latae<br>mean (%), [95% CI] |                       | Rectus abdominis<br>mean (%), [95% CI] |                        | External oblique<br>mean (%), [95% CI] |                       |
|-------------------------------|--|---------------------------------------|-----------------------|---|-----------------------|--|------------------------|--|-----------------------|
|                               |  | Ipsilateral                           | Contralateral         | Ipsilateral                               | Contralateral         | Ipsilateral                            | Contralateral          | Ipsilateral                            | Contralateral         |
| AL<br>Hypertonic<br>Injection | 0° adduction                             | 93.7<br>[79.1,108.4]                  | 96.5<br>[86.6,106.5]  | 99.1<br>[78.3,119.9]                      | 102.8<br>[85.5,120.2] | 115.5<br>[78.6,12.5]                   | 119.8<br>[87.0,152.7]  | 116.3<br>[84.1,148.4]                  | 115.5<br>[87.9,143.1] |
|                               | 45° adduction                            | 98.9<br>[87.4,110.4]                  | 98.5<br>[88.9,108.2]  | 120.9<br>[89.4,152.3]                     | 121.5<br>[91.6,151.3] | 116.5<br>[94.6,138.4]                  | 106.2<br>[90.7,121.6]  | 116.2<br>[93.0,139.4]                  | 117.2<br>[88.4,146.0] |
|                               | 90° adduction                            | 103.0<br>[90.0,116.0]                 | 106.2<br>[93.2,119.3] | 101.3<br>[90.7,111.8]                     | 128.1<br>[88.7,167.5] | 110.2<br>[92.8,127.6]                  | 102.9<br>[93.2,112.6]  | 105.4<br>[87.4,123.5]                  | 118.3<br>[97.1,139.5] |
|                               | Resisted abdominal<br>crunch             | 101.7<br>[89.3,114.0]                 | 102.3<br>[87.3,117.4] | 138.6<br>[105.5,171.7]                    | 103.0<br>[85.2,120.8] | 98.0<br>[87.6,108.4]                   | 106.1<br>[96.1,116.1]  | 104.8<br>[81.3,128.4]                  | 94.9<br>[83.6,106.2]  |
|                               | Ipsilateral Resisted<br>oblique crunch   | 117.0<br>[87.1,147.0]                 | 110.1<br>[98.3,121.8] | 102.5<br>[83.8,121.3]                     | 108.6<br>[82.3,135.0] | 119.8<br>[85.6,153.9]                  | 119.4<br>[93.2,145.5]  | 103.5<br>[82.5,124.5]                  | 109.4<br>[82.0,136.8] |
|                               | Contralateral Resisted<br>oblique crunch | 125.8<br>[89.8,161.8]                 | 108.6<br>[99.0,118.2] | 121.5<br>[81.2,161.9]                     | 129.7<br>[96.1,163.2] | 105.3<br>[88.7,121.9]                  | 99.1<br>[84.2,113.9]   | 100.1<br>[83.5,116.6]                  | 100.0<br>[86.4,113.6] |
| RF<br>Hypertonic<br>Injection | 0° adduction                             | 107.3<br>[96.5,118.1]                 | 111.2<br>[98.0,124.5] | 110.6<br>[94.7,126.5]                     | 107.9<br>[85.7,130.1] | 133.0<br>[43.8,222.2]                  | 108.0<br>[64.4,151.7]  | 105.1<br>[87.3,123.0]                  | 101.4<br>[84.2,118.7] |
|                               | 45° adduction                            | 106.1<br>[97.2,115.0]                 | 105.1<br>[97.5,112.6] | 96.5<br>[75.2,117.9]                      | 118.6<br>[86.5,150.6] | 98.3<br>[90.0,106.6]                   | 100.6<br>[91.7,109.5]  | 104.1<br>[88.7,119.5]                  | 102.8<br>[90.1,115.5] |
|                               | 90° adduction                            | 106.3<br>[93.0,119.6]                 | 106.2<br>[91.9,120.6] | 128.9<br>[100.7,149.1]                    | 116.8<br>[92.9,140.7] | 111.6<br>[93.7,129.6]                  | 116.0<br>[95.1,137.0]  | 109.0<br>[92.7,125.2]                  | 105.5<br>[88.8,122.3] |
|                               | Resisted abdominal<br>crunch             | 103.0<br>[90.1,116.0]                 | 102.1<br>[94.4,109.7] | 111.6<br>[83.3,140.0]                     | 115.9<br>[95.6,136.2] | 110.3<br>[101.0,119.5]                 | 113.9<br>[102.8,125.0] | 108.8<br>[83.6,134.0]                  | 108.2<br>[85.5,130.9] |
|                               | Ipsilateral Resisted<br>oblique crunch   | 108.0<br>[83.9,132.1]                 | 100.5<br>[80.8,120.3] | 97.0<br>[86.3,107.7]                      | 104.1<br>[83.5,124.6] | 111.8<br>[88.9,134.8]                  | 113.3<br>[98.4,128.3]  | 112.2<br>[93.3,131.1]                  | 111.1<br>[96.0,126.2] |
|                               | Contralateral Resisted<br>oblique crunch | 92.1<br>[72.5,111.7]                  | 92.8<br>[77.4,108.1]  | 91.7<br>[73.2,110.2]                      | 85.6<br>[67.7,103.5]  | 92.6<br>[78.0,107.1]                   | 95.1<br>[79.4,110.8]   | 93.7<br>[76.5,110.9]                   | 96.2<br>[72.7,119.6]  |

**Supplementary Table 4.** Mean normalised RMG-EMG [95%CI] during the clinical tests in the post-pain condition after control injections into the groin (AL isotonic injections) and thigh (RF isotonic injections). The RMS-EMG is normalised to baseline (100%).

| Injection                   | Test position                            | Adductor longus       |                        | Tensor fascia latae    |                       | Rectus abdominis      |                       | External oblique       |                        |
|-----------------------------|--|-----------------------|------------------------|------------------------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|
|                             |  | Ipsilateral           | Contralateral          | Ipsilateral            | Contralateral         | Ipsilateral           | Contralateral         | Ipsilateral            | Contralateral          |
| AL<br>Isotonic<br>Injection | 0° adduction                             | 101.8<br>[88.5,115.1] | 111.0<br>[94.3,127.8]  | 113.5<br>[80.1,146.9]  | 103.8<br>[71.2,136.4] | 118.0<br>[93.4,142.6] | 118.2<br>[89.3,147.1] | 104.1<br>[84.4,123.8]  | 117.6<br>[91.0,144.1]  |
|                             | 45° adduction                            | 110.6<br>[97.3,123.9] | 109.4<br>[94.8,124.0]  | 129.9<br>[79.0,180.8]  | 114.2<br>[89.5,138.9] | 125.3<br>[75.8,174.8] | 125.6<br>[87.4,163.7] | 125.8<br>[85.6,166.1]  | 117.7<br>[98.15,137.2] |
|                             | 90° adduction                            | 105.5<br>[86.7,124.3] | 103.7<br>[92.2,115.1]  | 105.1<br>[78.5,131.7]  | 104.6<br>[82.0,127.2] | 89.1<br>[70.8,107.4]  | 89.1<br>[74.5,107.4]  | 101.2<br>[85.1,105.4]  | 104.9<br>[86.2,123.7]  |
|                             | Resisted abdominal<br>crunch             | 104.8<br>[84.6,124.9] | 113.9<br>[95.3,132.5]  | 95.9<br>[75.9,116.0]   | 87.4<br>[68.6,106.1]  | 106.4<br>[86.1,126.7] | 110.6<br>[95.0,126.1] | 104.3<br>[94.0,114.6]  | 99.4<br>[90.9,108.0]   |
|                             | Ipsilateral Resisted<br>oblique crunch   | 100.2<br>[83.3,117.2] | 126.3<br>[96.6,155.9]  | 116.5<br>[83.4,149.7]  | 113.6<br>[79.6,147.7] | 98.8<br>[83.6,114.0]  | 103.8<br>[87.7,119.9] | 92.6<br>[76.0,109.3]   | 97.1<br>[80.9,113.2]   |
|                             | Contralateral Resisted<br>oblique crunch | 117.1<br>[88.9,145.4] | 97.5<br>[78.5,116.5]   | 127.7<br>[106.0,149.4] | 107.2<br>[64.5,149.9] | 129.3<br>[89.5,169.1] | 134.0<br>[83.4,184.6] | 97.3<br>[83.5,111.1]   | 116.9<br>[82.5,151.3]  |
| RF<br>Isotonic<br>Injection | 0° adduction                             | 107.4<br>[93.1,121.8] | 115.1<br>[101.4,128.8] | 180.8<br>[54.3,307.2]  | 118.6<br>[85.7,151.6] | 131.2<br>[95.1,167.3] | 134.1<br>[93.7,174.5] | 145.6<br>[104.1,187.2] | 132.3<br>[96.5,168.1]  |
|                             | 45° adduction                            | 101.5<br>[91.0,112.1] | 100.2<br>[89.6,110.8]  | 133.3<br>[85.64,180.9] | 150.9<br>[92.1,209.7] | 91.0<br>[76.0,106.0]  | 86.7<br>[73.9,99.4]   | 91.6<br>[78.7,104.5]   | 94.4<br>[78.9,109.9]   |
|                             | 90° adduction                            | 100.2<br>[89.4,110.9] | 99.6<br>[89.4,109.8]   | 133.9<br>[88.4,179.5]  | 163.0<br>[87.9,238.2] | 81.7<br>[67.8,95.6]   | 82.6<br>[70.9,94.3]   | 89.2<br>[75.1,108.9]   | 89.2<br>[73.8,104.6]   |
|                             | Resisted abdominal<br>crunch             | 112.9<br>[89.0,136.9] | 103.1<br>[87.0,119.1]  | 102.1<br>[78.8,125.4]  | 122.5<br>[78.7,166.3] | 102.1<br>[80.3,123.9] | 103.4<br>[93.3,113.5] | 99.2<br>[86.9,111.6]   | 106.6<br>[95.4,117.8]  |
|                             | Ipsilateral Resisted<br>oblique crunch   | 111.1<br>[82.1,140.1] | 110.9<br>[99.2,122.6]  | 99.9<br>[77.7,122.1]   | 167.3<br>[39.3,295.4] | 100.6<br>[84.1,117.1] | 117.7<br>[95.7,139.7] | 102.2<br>[88.3,116.1]  | 110.6<br>[88.0,133.1]  |
|                             | Contralateral Resisted<br>oblique crunch | 101.2<br>[83.0,119.4] | 97.5<br>[82.0,112.9]   | 128.2<br>[80.2,176.2]  | 97.9<br>[83.8,111.7]  | 98.8<br>[80.9,116.7]  | 103.9<br>[89.8,118.1] | 96.7<br>[83.8,109.6]   | 100.5<br>[87.5,113.5]  |